The molecular events that mediate cholecystokinin (CCK)- 
Introduction
Cholecystokinin (CCK) is a gastrointestinal peptide hormone that is the predominant physiological stimulant of pancreatic enzyme secretion. However, our understanding ofthe molecular events mediating this process is limited because of the complex receptor-binding and concentration-response characteristics of this hormone and our inability to correlate the occupancy of a binding site with intracellular events leading to enzyme secretion.
CCK has an unusual concentration-response relationship, in which increasing concentrations of hormone stimulate pancreatic secretion up to a maximum, whereas supramaximal concentrations inhibit secretion (1) . To explain this, a model has been proposed in which two classes of hormone binding sites exist, a high-affinity site that stimulates secretion and a low-affinity site that inhibits secretion (1) . Indeed, direct CCK radioligand binding to pancreatic acini have demonstrated two classes of binding sites (1) ; ligands selective for each class, however, have not been described. In addition, only a single class of CCK-binding sites has been observed on pancreatic membranes (2) . Whereas this site has been biochemically characterized by affinity labeling (3) (4) (5) , the relationship between this site and those present on acini is unclear, and it has been debated whether this protein represents the receptor that mediates CCK-stimulated enzyme secretion.
Several pancreatic intracellular events involving a guanine nucleotide-binding protein, phospholipase C, inositol lipids, intracellular calcium, and protein kinases have been described to occur in response to CCK (6) . It is unclear which of these is related to occupancy of each binding site, and which truly mediate enzyme secretion. It is currently generally accepted that the proximal events in this cascade include association and activation of a guanine nucleotide-binding protein, activation of phospholipase C, and stimulation of inositol lipid metabolism (6) .
In (7) . However, synthesis was initiated by coupling the aspartic acid-phenethyl ester fl-carboxyl group to the resin using an acid-labile spacer.
Peptides were radioiodinated using N-chloro-benzenesulfonamide and purified by HPLC to 2,000 Ci/mmol, using the method we have previously described (3) .
Tissue preparations. Enriched pancreatic plasma membranes were prepared from 125-150-g male Sprague-Dawley rats (3) . Dispersed pancreatic acini were prepared from similar animals by sequential enzymatic and mechanical dissociation (9 The radioiodinated OPE-analogue bound in a saturable manner to both pancreatic acini and membranes, with characteristics similar in both (Kd = 16 nM) (Fig. 2 A) . Computer analysis of these data using the LIGAND program (12) Hill coefficient = 0.3) and only one site on plasma membranes (Kd = 0.8 nM) (Fig. 2 B) .
Evidence that the site that binds the OPE-analogue was indeed a CCK-binding site included the abilities of both this analogue and CCK to compete for binding of each other (Fig.  2, C and D) , and the ability of the specific CCK receptor antagonist L-364,7 18 (Merck, Sharp and Dohme, West Point, PA) to compete for binding of both (Fig. 2 E) . Interestingly, L-364,718 competition for binding of 125I-OPE-analogue to acini demonstrated a single binding site, whereas its competition for binding of the native CCK-radioligand demonstrated two classes of binding sites (Fig. 2 E) . Furthermore, close correlation existed between occupancy of the OPE-analoguebinding site and stimulation of pancreatic secretion, with 95% of sites occupied at maximal secretion ( Figs. 1 and 2 A) , suggesting that this probe interacts with the receptor relevant in CCK-stimulated secretion in a manner that obeys the mass action law.
When acini were incubated with native CCK, a second class of binding sites was evident (Fig. 2, B, C, and D) , and the OPE-analogue was also able to bind to that site (Fig. 2, C and  D) . However, this analogue acted as a competitive antagonist at that site, reversing the supramaximal inhibition of enzyme secretion that has been correlated with its occupancy by CCK (1) (Fig. 1) . The glycoprotein that bound the OPE-analogue on both acini and membranes was biochemically characterized by affinity labeling to be the same molecule labeled by a series of CCK receptor probes with sites of covalent attachment that span the receptor-binding domain (3, 4) (Fig. 3) . '25l-D-TyrGly[(Nle2ti31,-pNo2-Phe33)CCK-26-33], a CCK receptor probe possessing a photolabile nitro-phenylalanyl moiety within the theoretical receptor-binding domain (4) , labeled a M, = 85,000-95,000 protein on pancreatic membranes that was inhibited in a concentration-dependent manner by the OPEanalogue. Radiolabeled OPE-analogue, when used with disuccinimimidyl suberate (Fig. 3) or m-maleimidobenzoyl N-hydroxysuccinimide ester (data not shown), labeled the same Mr = 85,000-95,000 protein on pancreatic membranes and acini as that labeled by the CCK receptor probe, and this was also inhibited in a concentration-dependent manner by CCK-8 or by the unlabeled OPE-analogue. Using disuccinimidyl suberate, an additional band of Mr = 52,000 was saturably labeled; however, this was not consistently seen and was much less prominent when using m-maleimidobenzoyl N-hydroxysuccinimide-ester. The major Mr = 85,000-95,000 protein labeled by 125I-OPE-analogue was deglycosylated with endo F to yield the same M, = 42,000 core protein as that labeled by a series of CCK-receptor probes (3) (Fig. 3) . Staphylococcus aureus V8 protease peptide mapping of the labeled protein also confirmed this identity (data not shown).
The postulated proximal event in CCK-induced secretion is the association and activation of a guanine nucleotide-binding protein (14) . The role of this protein can be demonstrated using the nonhydrolyzable guanosine triphosphate analogue, 5'-guanylyl-imidodiphosphate (Gpp(NH)p), to inhibit CCK binding and to increase dissociation of CCK from its receptor Cholecystokinin-stimulated Pancreatic Secretion 323 . Whereas native CCK clearly demonstrates this activity, no such event occurred under conditions in which the OPEanalogue stimulated enzyme secretion (Fig. 2 F) .
Discussion
We have designed and synthesized a radioiodinated analogue of CCK that is a fully efficacious stimulant of pancreatic secretion, but which, unlike native hormone, does not exhibit supramaximal inhibition of secretion. The OPE-analogue has allowed us to observe directly the functional characteristics of the binding site that mediates CCK-stimulated pancreatic secretion, and to biochemically characterize that site. The differences in binding and second messenger activity between this analogue and native CCK provide important insights into the mechanism of action of this hormone. Unlike CCK, which binds to two classes of sites on acini, this analogue appears to bind to only one class of sites in the absence of CCK. Evidence that this site is indeed a CCK-binding site includes the abilities of both this analogue and CCK to compete for binding of each other, and the ability of the CCK receptor antagonist L364,7 18 to compete for binding of both. Of particular importance is the close correlation between occupancy of this site by the OPE-analogue and stimulation of enzyme secretion. This suggests that this probe interacts with the relevant receptor in CCK-stimulated secretion.
Biochemical characterization of the OPE-analogue-binding site using affinity-labeling techniques has identified a Mr = 85,000-95,000 glycoprotein on both pancreatic acini and membranes. This is the same size as the protein that has been labeled by a series of CCK receptor probes with sites of covalent attachment that span the receptor-binding domain (3, 4) . Further confirmation that the OPE-analogue-binding site is the same as that labeled by the other probes was its deglycosylation to the same-size core protein of Mr = 42,000, and its similar protease peptide mapping pattern.
These experiments also provide interesting insight into the second class of CCK-binding sites (low affinity), previously proposed as mediating inhibition of enzyme secretion (1). Although the OPE-analogue does not express supramaximal inhibition of secretion, it is able to bind to this site, where it behaves as a competitive antagonist, reversing CCK-induced supramaximal inhibition of enzyme secretion. The different activities of CCK and the OPE-analogue provide an opportunity to sort out the intracellular events associated with activation of the high-affinity CCK-binding site which lead to stimulation ofsecretion, from those associated with activation ofthe low-affinity CCK-binding site that lead to inhibition of secretion.
Note that the second class of CCK-binding sites is only observed on intact cells and not on plasmalemmal membranes from those cells. Also, intact cells express only a single binding site when incubated at 40C (16) . This may suggest that the expression of the second class of CCK-binding sites may actually depend on a temperature-dependent intracellular event. Perhaps those events that are stimulated by CCK, but not by the OPE-analogue, may be responsible for expression of the low-affinity site on the cell surface, or even for induction of a change in the affinity of the high-affinity binding site. The latter possibility may explain why only a single molecule has been affinity labeled by the most ideal CCK-based receptor probes, which are covalently attached via functional groups near or within the receptor-binding domain (3, 4) .
The postulated proximal event in CCK-induced pancreatic activity is the association and activation of a guanine nucleotide-binding protein ( 14) . The role ofthis protein can be demonstrated experimentally by incubation with the nonhydrolyzable guanosine triphosphate analogue, 5'-guanylyl-imidodiphosphate, which inhibits CCK binding and increases dissociation of CCK from its receptor (15) . Whereas native CCK clearly induces guanine nucleotide-binding protein activity, no such event seems to occur under conditions that the OPE-analogue stimulates maximal enzyme secretion. This suggests the presence of a novel intracellular pathway not previously recognized to mediate CCK-stimulated pancreatic enzyme secretion. The recent observation that another related OPE-analogue of CCK does not induce phosphatidyl inositol hydrolysis, a more distal event in this postulated cascade, is consistent with this (8) .
Thus, this unique CCK analogue provides evidence that the Mr = 85,000-95,000 pancreatic plasma membrane protein represents the proximal step in stimulus-secretion coupling. The previously proposed pathway ofguanine nucleotide-binding protein association and activation leading to activation of phospholipase C and inositol lipid metabolism is not activated by this secretagogue, and may mediate CCK-induced supramaximal inhibition of secretion rather than CCK-stimulated pancreatic secretion. The mechanism of this stimulation is yet to be determined.
